Do We Need Biomarkers to Predict Tumor Hyper-Progression Following Immunotherapy? – AJMC.com Managed Markets Network
|
Do We Need Biomarkers to Predict Tumor Hyper-Progression Following Immunotherapy?
AJMC.com Managed Markets Network The study evaluated tumor biopsies of 155 stage IV cancer patients who had received immunotherapy treatments—inhibitors of CTLA-4, programmed death 1 (PD-1), programmed death ligand-1 (PD-L1), or other immunotherapy agents. Hyper-progression … |
